IJDDP/
Articles/
2504000149
  • Open Access
  • Review
Small Leucine Rich Proteoglycan in Fibrotic Diseases: New Frenemies?
  • Jiayu Guo 1, 2,   
  • Yan Wang 1, 2,   
  • Haihai Liang 1, 2, 3, *,   
  • Baofeng Yang 1, 2, 3, *

Received: 27 Apr 2023 | Accepted: 02 Jun 2023 | Published: 27 Jun 2023

Abstract

The human body is a complex organism with self-regulating ability and can cope with external pressures and challenges. To protect the body from damage during exercise or confrontations, beneath the human epidermal layer, the human body has evolved a coverall gown: the extracellular matrix (ECM). ECM provides a suitable space for the survival and activity of cells in the body, and affects the behavior of cells through signal transduction system. Proteoglycans, particularly the small leucine rich proteoglycan (SLRP) family, have been shown to be molecules that play important roles in matrix remodeling and organ fibrosis, such as by affecting ECM components or altering the intracellular environment. But in recent years reports of SLRP families, their manifestations in different organs have not been consistent. Recent studies suggest that proteoglycans entering the blood in a soluble form hold promise as diagnostic biomarkers of organ fibrosis and may provide novel therapeutic strategies for fibrotic diseases. Herein, we discuss and review studies of SLRPs in multi-organ fibrotic diseases.

References 

  • 1.
    Hu H. H.; Cao G.; Wu X. Q.; et al. Wnt signaling pathway in aging-related tissue fibrosis and therapies. Ageing Res. Rev., 2020, 60: 101063. doi:10.1016/j.arr.2020.101063.
  • 2.
    Kong X.; Liu H.; He X.; et al. Unraveling the Mystery of Cold Stress-Induced Myocardial Injury. Front. Physiol., 2020, 11: 580811. doi:10.3389/fphys.2020.580811.
  • 3.
    Maldonado H.; Hagood J.S. Cooperative signaling between integrins and growth factor receptors in fibrosis. J. Mol. Med., 2021, 99(2): 213-224. doi:10.1007/s00109-020-02026-2.
  • 4.
    Li L.; Zhao Q.; Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol., 2018, 68-69: 490-506. doi:10.1016/j.matbio.2018.01.013.
  • 5.
    Chaudhuri O.; Cooper-White J.; Janmey P.A.; et al. Effects of extracellular matrix viscoelasticity on cellular behaviour. Nature, 2020, 584(7822): 535-546. doi:10.1038/s41586-020-2612-2.
  • 6.
    Bonnans C.; Chou J.; Werb Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol., 2014, 15(12): 786-801. doi:10.1038/nrm3904.
  • 7.
    Theocharis A. D.; Skandalis S. S.; Gialeli C.; et al. Extracellular matrix structure. Adv. Drug Deliv. Rev., 2016, 97: 4-27. doi:10.1016/j.addr.2015.11.001.
  • 8.
    Liu C.; Pei M.; Li Q.; et al. Decellularized extracellular matrix mediates tissue construction and regeneration. Front. Med., 2022, 16(1): 56-82. doi:10.1007/s11684-021-0900-3.
  • 9.
    Iozzo R. V.; Schaefer L. Proteoglycan form and function: A comprehensive nomenclature of proteoglycans. Matrix Biol., 2015, 42: 11-55. doi:10.1016/j.matbio.2015.02.003
  • 10.
    Christensen G.; Herum K. M.; LundeI. G. Sweet, yet underappreciated: Proteoglycans and extracellular matrix remodeling in heart disease. Matrix Biol., 2019, 75-76: 286-299. doi:10.1016/j.matbio.2018.01.001
  • 11.
    Westermann D.; Mersmann J.; Melchior A.; et al. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation, 2008, 117(10): 1269-76. doi:10.1161/CIRCULATIONAHA.107.714147
  • 12.
    Prydz K.; Dalen K. T. Synthesis and sorting of proteoglycans. J. Cell Sci., 2000, 113 Pt 2: 193-205. doi:10.1242/jcs.113.2.193.
  • 13.
    Chen S.; Birk D. E. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. FEBS J., 2013, 280(10): 2120-37. doi:10.1111/febs.12136.
  • 14.
    Nastase M. V.; Janicova A.; Roedig H.; et al. Small Leucine-Rich Proteoglycans in Renal Inflammation: Two Sides of the Coin. J. Histochem. Cytochem., 2018, 66(4): 261-272. doi:10.1369/0022155417738752.
  • 15.
    Westergren-Thorsson G.; Hernnäs J.; SärnstrandB.; et al. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. J. Clin. Invest., 1993, 92(2): 632-7. doi:10.1172/JCI116631.
  • 16.
    Barallobre-Barreiro J.; Gupta S. K.; ZoccaratoA.; et al. Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation. Circulation, 2016, 134(11): 817-32. doi:10.1161/CIRCULATIONAHA.115.016423
  • 17.
    Meyer D. H.; Krull N.; Dreher K. L. Gressner A. M. Biglycan and decorin gene expression in normal and fibrotic rat liver: cellular localization and regulatory factors. Hepatology, 1992, 16(1): 204-16. doi: 10.1002/hep.1840160131. doi:10.1002/hep.1840160131.
  • 18.
    Schaefer L; Mihalik D.; Babelova A.; et al. Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury. Am. J. Pathol., 2004,165(2): 383-96. doi: 10.1016/S0002-9440(10)63305-6.
  • 19.
    Stokes M. B.; Holler S.; Cui Y.; et al. Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int., 2000, 57(2): 487-98. doi: 10.1046/j.1523-1755.2000.00868.x.
  • 20.
    Shimizu-HirotaR.; SasamuraH.; KurodaM.; et al. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ. Res., 2004, 94(8): 1067-74. doi: 10.1161/01.RES.0000126049.79800.CA.
  • 21.
    Beetz N.; Rommel C.; Schnick T.; et al. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload. J. Mol. Cell. Cardiol., 2016, 101: 145-155. doi: 10.1016/j.yjmcc.2016.10.011. Epub 2016 Oct 24.
  • 22.
    Yu M.; He X.; Song X.; et al. Biglycan promotes hepatic fibrosis through activating heat shock protein 47. Liver Int., 2023, 43(2): 500-512. doi: 10.1111/liv.15477. Epub 2022 Nov 21.
  • 23.
    -Maciejewski C. C.; Honardoust D.; Tredget E. E.; et al. Differential expression of class I small leucine-rich proteoglycans in an animal model of partial bladder outlet obstruction. J. Urol., 2012, 188(4 Suppl): 1543-8. doi: 10.1016/j.juro.2012.03.045. Epub 2012 Aug 19.
  • 24.
    Huang C.; Sharma A.; Thakur R.; et al. Asporin, an extracellular matrix protein, is a beneficial regulator of cardiac remodeling. Matrix Biol., 2022, 110: 40-59. doi: 10.1016/j.matbio.2022.04.005. Epub 2022 Apr 22.
  • 25.
    HuangS.; LaiX.; YangL.; et al. Asporin Promotes TGF-β-induced Lung Myofibroblast Differentiation by Facilitating Rab11-Dependent Recycling of TβRI. Am. J. Respir. Cell Mol. Biol., 2022, 66(2): 158-170. doi: 10.1165/rcmb.2021-0257OC.
  • 26.
    Qian W.; Xia S.; Yang X.; et al. Complex Involvement of the Extracellular Matrix, Immune Effect, and Lipid Metabolism in the Development of Idiopathic Pulmonary Fibrosis. Front. Mol. Biosci., 2022, 8: 800747. doi: 10.3389/fmolb.2021.800747.
  • 27.
    Engebretsen K. V.; Lunde I. G.; Strand M. E.; et al. Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. FEBS J., 2013, 280(10): 2382-98. doi: 10.1111/febs.12235. Epub 2013 Apr 2.
  • 28.
    Rixon C.; Andreassen K.; Shen X.; et al. Lumican accumulates with fibrillar collagen in fibrosis in hypertrophic cardiomyopathy. ESC Heart Fail., 2023, 10(2): 858-871. doi: 10.1002/ehf2.14234. Epub 2022 Nov 29.
  • 29.
    Mohammadzadeh N.; Melleby A. O.; PalmeroS.; et al. Moderate Loss of the Extracellular Matrix Proteoglycan Lumican Attenuates Cardiac Fibrosis in Mice Subjected to Pressure Overload. Cardiology, 2020, 145(3): 187-198. doi: 10.1159/000505318. Epub 2020 Jan 22. PMID: 31968347;
  • 30.
    Pilling D.; Vakil V.; Cox N.; et al. TNF-α-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation. Proc. Natl. Acad. Sci. U S A., 2015, 112(38): 11929-34. doi: 10.1073/pnas.1507387112. Epub 2015 Sep 8.
  • 31.
    KrishnanA.; LiX.; KaoW. Y.; et al. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab. Invest., 2012, 92(12): 1712-25. doi: 10.1038/labinvest.2012.121. Epub 2012 Sep 24.
  • 32.
    Hsieh L. T.; Nastase M. V.; Zeng-Brouwers J.; et al. Soluble biglycan as a biomarker of inflammatory renal diseases. Int. J. Biochem. Cell Biol., 2014, 54: 223-35. doi: 10.1016/j.biocel.2014.07.020. Epub 2014 Aug 1.
  • 33.
    Xiao D.; Liang T.; Zhuang Z.; et al. Lumican promotes joint fibrosis through TGF-β signaling. FEBS Open Bio., 2020, 10(11): 2478-2488. doi: 10.1002/2211-5463.12974. Epub 2020 Oct 25.
  • 34.
    AndenæsK.; LundeI. G.; MohammadzadehN.; et al. The extracellular matrix proteoglycan fibromodulin is upregulated in clinical and experimental heart failure and affects cardiac remodeling. PLoS One, 2018, 13(7): e0201422. doi: 10.1371/journal.pone.0201422.
  • 35.
    Soo C.; Hu F. Y.; Zhang X.; et al. Differential expression of fibromodulin, a transforming growth factor-beta modulator, in fetal skin development and scarless repair. Am. J. Pathol., 2000, 157(2): 423-33. doi: 10.1016/s0002-9440(10)64555-5.
  • 36.
    Venkatesan N.； Ebihara T.； RoughleyP. J.; et al. Alterations in large and small proteoglycans in bleomycin-induced pulmonary fibrosis in rats. Am. J. Respir. Crit. Care. Med., 2000, 161(6): 2066-73. doi: 10.1164/ajrccm.161.6.9909098.
  • 37.
    An W.; Zhu J. W.; Jiang F.; et al. Fibromodulin is upregulated by oxidative stress through the MAPK/AP-1 pathway to promote pancreatic stellate cell activation. Pancreatology., 2020, 20(2): 278-287. doi: 10.1016/j.pan.2019.09.011. Epub 2019 Sep 26.
  • 38.
    WoessnerM. N.; HiamD.; SmithC.; et al. Osteoglycin Across the Adult Lifespan. J. Clin. Endocrinol. Metab., 2022, 107(4): e1426-e1433. doi: 10.1210/clinem/dgab861.
  • 39.
    Van Aelst L. N.; Voss S.; Carai P.; et al. Osteoglycin prevents cardiac dilatation and dysfunction after myocardial infarction through infarct collagen strengthening. Circ. Res., 2015, 116(3): 425-36. doi: 10.1161/CIRCRESAHA.116.304599. Epub 2014 Dec 17.
  • 40.
    Tallquist M. D. Cardiac Fibroblast Diversity. Annu. Rev. Physiol., 2020, 82: 63-78. doi: 10.1146/annurev-physiol-021119-034527.
  • 41.
    Frangogiannis N. G. Cardiac fibrosis. Cardiovasc. Res., 2021, 117(6): 1450-1488. doi: 10.1093/cvr/cvaa324.
  • 42.
    Weis S. M.; Zimmerman S. D.; Shah M.; et al. A role for decorin in the remodeling of myocardial infarction. Matrix Biol., 2005, 24(4): 313-24. doi: 10.1016/j.matbio.2005.05.003.
  • 43.
    Isaka Y.; Brees D. K.; Ikegaya K.; et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med., 1996, 2(4): 418-23. doi: 10.1038/nm0496-418.
  • 44.
    Jahanyar J.; Joyce D. L.; Southard R. E.; et al. Decorin-mediated transforming growth factor-beta inhibition ameliorates adverse cardiac remodeling. J. Heart Lung Transplant., 2007, 26(1): 34-40. doi: 10.1016/j.healun.2006.10.005. Epub 2006 Nov 30.
  • 45.
    Yan W.; Wang P.; Zhao C. X.; et al. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum. Gene Ther., 2009, 20(10): 1190-200.
  • 46.
    SchaeferL.; DikicI. Autophagy: Instructions from the extracellular matrix. Matrix Biol., 2021, 100-101: 1-8. doi: 10.1016/j.matbio.2021.06.002. Epub 2021 Jul 2.
  • 47.
    Goyal A.; Neill T.; Owens R. T.; et al. Decorin activates AMPK, an energy sensor kinase, to induce autophagy in endothelial cells. Matrix Biol., 2014, 34: 46-54. doi: 10.1016/j.matbio.2013.12.011. Epub 2014 Jan 26.
  • 48.
    Torres A.; Gubbiotti M. A.; Iozzo R. V. Decorin-inducible Peg3 Evokes Beclin 1-mediated Autophagy and Thrombospondin 1-mediated Angiostasis. J. Biol. Chem., 2017, 292(12): 5055-5069. doi: 10.1074/jbc.M116.753632. Epub 2017 Feb 7.
  • 49.
    Chen C. G.; Gubbiotti M. A.; Kapoor A.; et al. Autophagic degradation of HAS2 in endothelial cells: A novel mechanism to regulate angiogenesis. Matrix Biol., 2020, 90: 1-19. doi: 10.1016/j.matbio.2020.02.001. Epub 2020 Feb 19.
  • 50.
    Heegaard A. M.; Corsi A.; Danielsen C. C.; et al. Biglycan deficiency causes spontaneous aortic dissection and rupture in mice. Circulation, 2007, 115(21): 2731-8. doi: 10.1161/CIRCULATIONAHA.106.653980. Epub 2007 May 14.
  • 51.
    Scuruchi M.; Mannino F.; Imbesi C.; et al. Biglycan Involvement in Heart Fibrosis: Modulation of Adenosine 2A Receptor Improves Damage in Immortalized Cardiac Fibroblasts. Int. J. Mol. Sci., 2023, 24(2): 1784. doi: 10.3390/ijms24021784.
  • 52.
    Melchior-Becker A.; Dai G.; Ding Z.; et al. Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype. J. Biol. Chem., 2011, 286(19): 17365-75. doi: 10.1074/jbc.M110.192682. Epub 2011 Mar 18.
  • 53.
    Mohammadzadeh N.; Lunde I. G.; Andenæs K.; et al. The extracellular matrix proteoglycan lumican improves survival and counteracts cardiac dilatation and failure in mice subjected to pressure overload. Sci. Rep., 2019, 9(1): 9206. doi: 10.1038/s41598-019-45651-9.
  • 54.
    Chen S. W.; Tung Y. C.; Jung S. M.; et al. Lumican-null mice are susceptible to aging and isoproterenol-induced myocardial fibrosis. Biochem. Biophys. Res. Commun., 2017, 482(4): 1304-1311. doi: 10.1016/j.bbrc.2016.12.033. Epub 2016 Dec 7.
  • 55.
    Kalamajski S.; Bihan D.; Bonna A.; et al. Fibromodulin Interacts with Collagen Cross-linking Sites and Activates Lysyl Oxidase. J. Biol. Chem., 2016, 291(15): 7951-60. doi: 10.1074/jbc.M115.693408. Epub 2016 Feb 18.
  • 56.
    Jazbutyte V.; Fiedler J.; Kneitz S.; et al. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr), 2013, 35(3): 747-62. doi: 10.1007/s11357-012-9407-9. Epub 2012 Apr 27.
  • 57.
    Deckx S.; Heggermont W.; Carai P.; et al. Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biol., 2018, 66: 110-124. doi: 10.1016/j.matbio.2017.09.002. Epub 2017 Sep 25.
  • 58.
    Zuo C.; Li X.; Huang J.; et al. Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling. Cardiovasc. Res., 2018, 114(5): 703-712. doi: 10.1093/cvr/cvy035.
  • 59.
    Fang Y.; Chang Z.; Xu Z.; et al. Osteoglycin silencing exerts inhibitory effects on myocardial fibrosis and epithelial/endothelial-mesenchymal transformation in a mouse model of myocarditis. Biofactors, 2020, 46(6): 1018-1030. doi: 10.1002/biof.1683. Epub 2020 Nov 3.
  • 60.
    Li X. L.; Yu F.; Li B. Y.; et al. The protective effects of grape seed procyanidin B2 against asporin mediates glycated low-density lipoprotein induced-cardiomyocyte apoptosis and fibrosis. Cell Biol. Int., 2020, 44(1): 268-277. doi: 10.1002/cbin.11229. Epub 2019 Sep 18.
  • 61.
    Zhang Y.; Fu C.; ZhaoS.; et al. PRELP promotes myocardial fibrosis and ventricular remodelling after acute myocardial infarction by the wnt/β-catenin signalling pathway. Cardiovasc. J. Afr., 2022, 33(5): 228-233. doi: 10.5830/CVJA-2022-001. Epub 2022 Jun 29.
  • 62.
    Parola M.; Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med., 2019, 65: 37-55. doi: 10.1016/j.mam.2018.09.002. Epub 2018 Sep 13.
  • 63.
    Bataller R.; Brenner D. A. Liver fibrosis. J. Clin. Invest. 2005 ;115(2):209-18. doi: 10.1172/JCI24282. Erratum in: J. Clin. Invest., 2005, 115(4):1100.
  • 64.
    Baghy K., Dezso K., Laszlo V., et al. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab. Invest. 2010, 439-451.doi:10.1038/labinvest.2010.172
  • 65.
    Jang Y. O.; Cho M. Y.; Yun C. O.; et al. Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis. Stem Cells Transl. Med., 2016, 5(9): 1247-56. doi: 10.5966/sctm.2015-0323. Epub 2016 Jun 30.
  • 66.
    Baghy K.; Iozzo R. V.; Kovalszky I. Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J. Histochem. Cytochem., 2012, 60(4): 262-8. doi: 10.1369/0022155412438104. Epub 2012 Jan 19.
  • 67.
    LiuJ.; ZhuS.; ZengL.; et al. DCN released from ferroptotic cells ignites AGER-dependent immune responses. Autophagy, 2022, 18(9): 2036-2049. doi: 10.1080/15548627.2021.2008692. Epub 2021 Dec 29.
  • 68.
    Schulz M.; Dieh l. V.; Trebicka J.; et al. Biglycan: A regulator of hepatorenal inflammation and autophagy. Matrix Biol., 2021, 100-101: 150-161. doi: 10.1016/j.matbio.2021.06.001. Epub 2021 Jun 10.
  • 69.
    Roedig H.; Damiescu R.; Zeng-Brouwers J.; et al. Danger matrix molecules orchestrate CD14/CD44 signaling in cancer development. Semin. Cancer Biol., 2020, 62: 31-47. doi: 10.1016/j.semcancer.2019.07.026. Epub 2019 Aug 11.
  • 70.
    Zeng-Brouwers J.; Pandey S.; Trebicka J.; et al. Communications via the Small Leucine-rich Proteoglycans: Molecular Specificity in Inflammation and Autoimmune Diseases. J. Histochem. Cytochem., 2020, 68(12): 887-906. doi: 10.1369/0022155420930303. Epub 2020 Jul 6.
  • 71.
    Li X.; Roife D.; Kang Y.; et al. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition. Oncogene, 2016, 35(37): 4881-90. doi: 10.1038/onc.2016.20. Epub 2016 Feb 15.
  • 72.
    Ptasinski V. A.; Stegmayr J.; Belvisi M. G.; et al. Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol., 2021, 65(4): 347-365. doi: 10.1165/rcmb.2020-0476TR.
  • 73.
    UpaguptaC.; ShimboriC.; AlsilmiR.; et al. Matrix abnormalities in pulmonary fibrosis. Eur. Respir. Rev., 2018, 27(148): 180033. doi: 10.1183/16000617.0033-2018.
  • 74.
    InuiN.; SakaiS.; KitagawaM. Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway. Int. J. Mol. Sci., 2021, 22(11): 6107. doi: 10.3390/ijms22116107.
  • 75.
    Kolb M.; Margetts P. J.; Galt T.; et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care. Med., 2001, 163(3 Pt 1): 770-7. doi: 10.1164/ajrccm.163.3.2006084.
  • 76.
    KolbM.; MargettsP. J.; SimeP. J.; et al. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol., 2001, 280(6): L1327-34. doi: 10.1152/ajplung.2001.280.6.L1327.
  • 77.
    Allawadhi P.; Singh V.; Khurana I.; et al. Decorin as a possible strategy for the amelioration of COVID-19. Med. Hypotheses, 2021, 152: 110612. doi: 10.1016/j.mehy.2021.110612. Epub 2021 May 20.
  • 78.
    Nastase M. V.; Iozzo R. V.; Schaefer L. Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology. Biochim. Biophys. Acta, 2014, 1840(8): 2460-70. doi: 10.1016/j.bbagen.2014.01.035. Epub 2014 Feb 5.
  • 79.
    Asakura S.; Kato H.; Fujino S.; et al. Role of transforming growth factor-beta1 and decorin in development of central fibrosis in pulmonary adenocarcinoma. Hum. Pathol., 1999, 30(2): 195-8. doi: 10.1016/s0046-8177(99)90275-7.
  • 80.
    Wang K.; Wang Y.; Cao Y.; et al. Lumican is elevated in the lung in human and experimental acute respiratory distress syndrome and promotes early fibrotic responses to lung injury. J. Transl. Med., 2022, 20(1): 392. doi: 10.1186/s12967-022-03597-z.
  • 81.
    Shi S.; Li H. Overexpressed microRNA-140 inhibits pulmonary fibrosis in interstitial lung disease via the Wnt signaling pathway by downregulating osteoglycin. Am. J. Physiol. Cell Physiol., 2020, 319(5): C895-C905. doi: 10.1152/ajpcell.00479.2019. Epub 2020 Aug 5.
  • 82.
    Rydell-Törmänen K.; Andréasson K.; Hesselstrand R.; et al. Absence of fibromodulin affects matrix composition, collagen deposition and cell turnover in healthy and fibrotic lung parenchyma. Sci. Rep., 2014, 4: 6383. doi: 10.1038/srep06383.
  • 83.
    Li L.; Fu H.; Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat. Rev. Nephrol., 2022, 18(9): 545-557. doi: 10.1038/s41581-022-00590-z. Epub 2022 Jul 4.
  • 84.
    LiH.; DixonE. E.; WuH.; et al. Comprehensive single-cell transcriptional profiling defines shared and unique epithelial injury responses during kidney fibrosis. Cell Metab., 2022, 34(12): 1977-1998.e9. doi: 10.1016/j.cmet.2022.09.026. Epub 2022 Oct 19.
  • 85.
    Leaf I. A.; Duffield J. S. What can target kidney fibrosis? Nephrol. Dial. Transplant., 2017, 32(suppl_1): i89-i97. doi: 10.1093/ndt/gfw388.
  • 86.
    Stokes M. B.; Hudkins K. L.; Zaharia V.; et al. Up-regulation of extracellular matrix proteoglycans and collagen type I in human crescentic glomerulonephritis. Kidney Int., 2001, 59(2): 532-42. doi: 10.1046/j.1523-1755.2001.059002532.x.
  • 87.
    Nastase M. V.; Zeng-Brouwers J.; Beckmann J.; et al. Biglycan, a novel trigger of Th1 and Th17 cell recruitment into the kidney. Matrix Biol., 2018, 68-69: 293-317. doi: 10.1016/j.matbio.2017.12.002. Epub 2017 Dec 15.
  • 88.
    Nakamura T.; Bonnard B.; Palacios-Ramirez R.; et al. Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury. Int. J. Mol. Sci., 2022, 23(12): 6680. doi: 10.3390/ijms23126680.
  • 89.
    Merline R.; Moreth K.; Beckmann J.; et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci. Signal., 2011, 4(199): ra75. doi: 10.1126/scisignal.2001868.
  • 90.
    Schaefer L.; Tsalastra W.; Babelova A.; et al. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin. Am. J. Pathol., 2007, 170(1): 301-15. doi: 10.2353/ajpath.2007.060497.
  • 91.
    Schaefer L.; Macakova K.; Raslik I.; et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am. J. Pathol., 2002, 160(3): 1181-91. doi: 10.1016/S0002-9440(10)64937-1.
  • 92.
    Vial C.; Gutiérrez J.; Santander C.; et al. Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. J. Biol. Chem., 2011, 286(27):24242-52. doi: 10.1074/jbc.M110.189365. Epub 2011 Mar 23.
  • 93.
    Zhu J.; Li Y.; Shen W.; et al. Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. J. Biol. Chem., 2007, 282(35):25852-63. doi: 10.1074/jbc.M704146200. Epub 2007 Jun 27.
  • 94.
    Mohan R. R.; Gupta R.; Mehan M. K.; et al. Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp. Eye. Res., 2010, 91(2): 238-45. doi: 10.1016/j.exer.2010.05.013. Epub 2010 May 28.
  • 95.
    Liu L.; Yu H.; Long Y.; et al. Asporin inhibits collagen matrix-mediated intercellular mechanocommunications between fibroblasts during keloid progression. FASEB J., 2021, 35(7): e21705. doi: 10.1096/fj.202100111R.
  • 96.
    Honardoust D.; Varkey M.; Hori K.; et al. Small leucine-rich proteoglycans, decorin and fibromodulin, are reduced in postburn hypertrophic scar. Wound Repair Regen., 2011, 19(3): 368-78. doi: 10.1111/j.1524-475X.2011.00677.x. Epub 2011 Apr 21.
  • 97.
    Jiang W.; Ting K.; Lee S.; et al. Fibromodulin reduces scar size and increases scar tensile strength in normal and excessive-mechanical-loading porcine cutaneous wounds. J. Cell. Mol. Med., 2018, 22(4): 2510-2513. doi: 10.1111/jcmm.13516. Epub 2018 Feb 1.
  • 98.
    Honardoust D.; Varkey M.; Marcoux Y.; et al. Reduced decorin, fibromodulin, and transforming growth factor-β3 in deep dermis leads to hypertrophic scarring. J. Burn. Care. Res., 2012, 33(2): 218-27. doi: 10.1097/BCR.0b013e3182335980.
  • 99.
    Andréasson K.; Gustafsson R.; Rydell-Törmänen K.; et al. Limited impact of fibromodulin deficiency on the development of experimental skin fibrosis. Exp. Dermatol., 2016, 25(7): 558-61. doi: 10.1111/exd.13012.
  • 100.
    Zheng Z.; Nguyen C.; Zhang X.; et al. Delayed wound closure in fibromodulin-deficient mice is associated with increased TGF-β3 signaling. J. Invest. Dermatol., 2011, 131(3): 769-78. doi: 10.1038/jid.2010.381. Epub 2010 Dec 30.
  • 101.
    Stoff A.; Rivera A. A.; Mathis J. M.; et al. Effect of adenoviral mediated overexpression of fibromodulin on human dermal fibroblasts and scar formation in full-thickness incisional wounds. J. Mol. Med., 2007, 85(5): 481-96. doi: 10.1007/s00109-006-0148-z. Epub 2007 Jan 12.
  • 102.
    Liu X. J.; Kong F. Z.; Wang Y. H.; et al. Lumican Accelerates Wound Healing by Enhancing α2β1 Integrin-Mediated Fibroblast Contractility. PLoS One, 2013, 8(6): e67124. doi: 10.1371/journal.pone.0067124.
  • 103.
    Chacón-Solano E.; León C.; Carretero M.; et al. Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis. Matrix Biol., 2022, 111: 189-206. doi: 10.1016/j.matbio.2022.06.007. Epub 2022 Jun 30.
  • 104.
    Moreth K.; Brodbeck R.; Babelova A.; et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J. Clin. Invest., 2010, 120(12): 4251-72. doi: 10.1172/JCI42213. Epub 2010 Nov 15.
  • 105.
    Nikaido T.; Tanino Y.; Wang X.; et al. Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis. J. Thorac. Dis., 2018, 10(9): 5346-5358. doi: 10.21037/jtd.2018.08.60.
  • 106.
    Kehlet S. N.; Bager C. L.; Willumsen N.; et al. Cathepsin-S degraded decorin are elevated in fibrotic lung disorders - development and biological validation of a new serum biomarker. BMC Pulm. Med., 2017, 17(1): 110. doi: 10.1186/s12890-017-0455-x.
  • 107.
    Ueland T.; Aukrust P.; Nymo S. H.; et al. Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. J. Card. Fail., 2015, 21(2): 153-9. doi: 10.1016/j.cardfail.2014.10.016. Epub 2014 Nov 7.
  • 108.
    Cengiz M.; Yilmaz G.; Ozenirler S. Serum Biglycan as a Diagnostic Marker for Non-Alcoholic Steatohepatitis and Liver Fibrosis. Clin. Lab., 2021, 67(3). doi: 10.7754/Clin.Lab.2020.200709.
  • 109.
    Ciftciler R.; Ozenirler S.; Yucel A. A.; et al. The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis Br. J. Clin. Lab. Anal., 2017, 31(5): e22109. doi: 10.1002/jcla.22109. Epub 2016 Dec 7.
  • 110.
    Romero R.; Mazaki-Tovi S.; Vaisbuch E.; et al. Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J. Matern. Fetal Neonatal Med., 2010, 23(12): 1344-59. doi: 10.3109/14767058.2010.482618. Epub 2010 May 26.
  • 111.
    Cheng J. M.; Akkerhuis K. M.; Meilhac O.; et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler, Thromb, Vasc, Biol., 2014, 34(5): 1078-84. doi: 10.1161/ATVBAHA.114.303486. Epub 2014 Mar 20.
  • 112.
    Motiwala S. R.; Szymonifka J.; Belcher A.; et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J. Cardiovasc. Transl. Res., 2017, 250-61. doi: 10.1007/s12265-013-9522-8. Epub 2013 Dec 6.
  • 113.
    Deckx S.; Heymans S.; Papageorgiou A. P. The diverse functions of osteoglycin: a deceitful dwarf, or a master regulator of disease? FASEB J., 2016, 30(8):2651-61. doi: 10.1096/fj.201500096R. Epub 2016 Apr 14.
  • 114.
    Baek S. H.; Cha R. H.; Kang S. W.; et al. Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. Tohoku. J. Exp. Med., 2017, 242(4): 281-290. doi: 10.1620/tjem.242.281.
  • 115.
    Hsu M. E.; Cheng Y. T.; Chang C. H.; et al. Level of serum soluble lumican and risks of perioperative complications in patients receiving aortic surgery. PLoS One, 2021, 16(3): e0247340. doi: 10.1371/journal.pone.0247340.
  • 116.
    Gu G.; Wan F.; Xue Y.; et al. Lumican as a novel potential clinical indicator for acute aortic dissection: A comparative study, based on multi-slice computed tomography angiography. Exp. Ther. Med., 2016, 11(3): 923-928. doi: 10.3892/etm.2016.3020. Epub 2016 Jan 22.
  • 117.
    Decaris M. L.; Li K. W.; Emson C. L.; et al. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood. Hepatology, 2017, 65(1): 78-88. doi: 10.1002/hep.28860. Epub 2016 Nov 15.
  • 118.
    Liu D.; Kong F.; Yuan Y.; et al. Decorin-Modified Umbilical Cord Mesenchymal Stem Cells (MSCs) Attenuate Radiation-Induced Lung Injuries via Regulating Inflammation, Fibrotic Factors, and Immune Responses. Int. J. Radiat. Oncol. Biol. Phys., 2018, 101(4) 945-956. doi: 10.1016/j.ijrobp.2018.04.007. Epub 2018 Apr 16.
  • 119.
    Shimizukawa M.; Ebina M.; Narumi K.; et al. Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. Am. J. Physiol. Lung Cell. Mol. Physiol., 2003, 284(3): L526-32. doi: 10.1152/ajplung.00131.2002.
  • 120.
    Vijayan A. N.; Solaimuthu A.; Murali P.; et al. Decorin mediated biomimetic PCL-gelatin nano-framework to impede scarring. Int. J. Biol. Macromol., 2022, 219: 907-918. doi: 10.1016/j.ijbiomac.2022.08.029. Epub 2022 Aug 8.
  • 121.
    Järvinen T. A. H.; Ruoslahti E. Generation of a multi-functional, target organ-specific, anti-fibrotic molecule by molecular engineering of the extracellular matrix protein, decorin. Br. J. Pharmacol., 2019, 176(1): 16-25. doi: 10.1111/bph.14374. Epub 2018 Jun 25.
  • 122.
    He R.; Lu Y.; Ren J.; et al. Decreased fibrous encapsulation and enhanced osseointegration in vitro by decorin-modified titanium surface. Colloids Surf. B Biointerfaces, 2017, 155: 17-24. doi: 10.1016/j.colsurfb.2017.03.055. Epub 2017 Mar 31.
  • 123.
    Chen G.; Zhu Y.; Liang X.; et al. The Effect of Lecithins Coupled Decorin Nanoliposomes on Treatment of Carbon Tetrachloride-Induced Liver Fibrosis. Biomed Res. Int., 2020, 8815904. doi: 10.1155/2020/8815904.
  • 124.
    Ding Q.; Wei Q.; Sheng G.; et al. The Preventive Effect of Decorin on Epidural Fibrosis and Epidural Adhesions After Laminectomy. Front. Pharmacol., 2021, 12: 774316. doi: 10.3389/fphar.2021.774316.
  • 125.
    Pietraszek K.; Brézillon S.; Perreau C.; et al. Lumican - derived peptides inhibit melanoma cell growth and migration. PLoS One, 2013, 8(10):e76232. doi: 10.1371/journal.pone.0076232.
  • 126.
    Rockey D. C.; Bell P. D.; Hill J. A. Fibrosis--a common pathway to organ injury and failure. N. Engl. J. Med., 2015, 372(12): 1138-49. doi: 10.1056/NEJMra1300575.
  • 127.
    Mao L.; Yang J.; Yue J.; et al. Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis. Matrix Biol., 2021, 95: 1-14. doi: 10.1016/j.matbio.2020.10.001. Epub 2020 Oct 13.
  • 128.
    Karamanou K.; Franchi M.; Vynios D; et al. Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator. Semin. Cancer Biol., 2020, 62: 125-133. doi: 10.1016/j.semcancer.2019.08.003. Epub 2019 Aug 8.
  • 129.
    Sengupta S.; Mondal M.; Prasasvi K. R.; et al. Differentiated glioma cell-derived fibromodulin activates integrin-dependent Notch signaling in endothelial cells to promote tumor angiogenesis and growth. Elife, 2022, 11: e78972. doi: 10.7554/eLife.78972.
  • 130.
    Oria V. O.; Zhang H.; Zito C. R.; et al. Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma. Cell. Mol. Life Sci., 2022, 79(7): 377. doi: 10.1007/s00018-022-04364-5.
  • 131.
    Wu H.; Xiang Z.; Huang G.; et al. BGN/FAP/STAT3 positive feedback loop mediated mutual interaction between tumor cells and mesothelial cells contributes to peritoneal metastasis of gastric cancer. Int. J. Biol. Sci., 2023, 19(2): 465-483. doi: 10.7150/ijbs.72218.
Share this article:
Download PDF
DOI
10.53941/ijddp.2023.100005
Issue
Volume 2, Issue 2
How to Cite
Guo, J.; Wang, Y.; Liang, H.; Yang, B. Small Leucine Rich Proteoglycan in Fibrotic Diseases: New Frenemies?. International Journal of Drug Discovery and Pharmacology 2023, 2 (2), 61–78. https://doi.org/10.53941/ijddp.2023.100005.
RIS
BibTex
Copyright & License
article copyright Image
Jiayu Guo, Yan Wang, Haihai Liang, Baofeng Yang